Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
|Podcasts|June 17, 2020
ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment
Author(s)Alex Delaney-Gesing
Dee Stephenson, MD, ABO, discusses the highlights of her presentation "Early Clinical Assessment of Aberration Neutral One-Piece Monofocal Toric IOL with Enhanced Optic Recovery and Alignment ORA" during the 2020 ASCRS virtual meeting.
Advertisement
Dee Stephenson, MD, ABO, speaks with Ophthalmology Times'® David Hutton on the highlights of her presentation "
Advertisement
Related to this article
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
3
Demodex blepharitis: Diagnosis, treatment response, and recurrence
4
Myopia control using spectacle lenses with highly aspherical lenslets
5